IgY Antibody Composition with Colostrum Matrix for Mucosal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies for mucosal infections face challenges due to limited binding attributes and diminished effectiveness when orally delivered, as they are susceptible to gastric acid and digestion enzymes, necessitating improved delivery mechanisms for IgY antibodies from avian eggs.
Innovation Solution
A composition combining IgY antibodies specific for multiple antigens with a protective matrix of non-hyperimmune colostrum, which can be administered as a solid, powder, cream, liquid, mist, aerosol, or spray, providing broad-spectrum protection against mucosal pathogens and biofilms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IgY antibodies are orally delivered to treat mucosal infections, then passive immunity is conferred, but effectiveness is diminished due to gastric acid and digestion enzymes
Solution Approach 1:
The patent uses colostrum as an intermediary substance to protect IgY antibodies from gastric acid and digestion enzymes. The colostrum matrix acts as a protective carrier that delivers the antibodies through the gastrointestinal tract intact, allowing them to reach the mucosal membranes where they can exert their therapeutic effect.
Solution Approach 2:
The patent changes the physical and chemical parameters of the antibody delivery system by embedding IgY antibodies within a colostrum matrix. This matrix modification alters the stability and resistance properties of the antibodies, enabling them to withstand the harsh gastrointestinal environment that would normally degrade free antibodies.
2Measurement precision
If highly specific antibodies are used to target specific pathogens, then targeted application is achieved, but binding range is excessively limited
Solution Approach 1:
The patent combines multiple IgY antibodies with different specificities against various pathogens into a single colostrum-based composition. This merging approach allows the formulation to maintain high specificity for each individual pathogen while simultaneously providing broad-spectrum coverage against multiple different pathogens through the collective action of the antibody mixture.
Solution Approach 2:
The colostrum matrix serves multiple functions: it protects antibodies from degradation, facilitates delivery to mucosal surfaces, and enables a single formulation to provide protection against multiple different pathogens. This multi-functionality allows the system to be universally applicable to various mucosal infections without requiring separate highly specific antibodies for each pathogen.
3Reliability
If mammalian colostrum is used to transfer antibodies to neonates, then passive immunity is provided, but the quantity of pathogen-specific antibodies is insufficient
Solution Approach 1:
The patent uses avian species as preliminary antibody production factories through immunization, allowing large quantities of pathogen-specific IgY antibodies to be accumulated in egg yolks before transfer to the neonate. This preliminary action in the avian system overcomes the limitation of insufficient pathogen-specific antibodies that would naturally be present in mammalian colostrum.
Solution Approach 2:
The patent employs avian IgY antibodies as a functional copy or substitute for mammalian IgG antibodies in colostrum. IgY antibodies from avian species perform the same protective function as mammalian antibodies would, but can be produced in much larger quantities through egg yolk, effectively copying the protective role while overcoming the quantity limitation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition confers effective passive immunity and broad-spectrum protection against mucosal pathogens and biofilms, with reduced toxicity and adverse reactions, offering a cost-effective alternative to existing treatments by leveraging controlled cross-reactivity and specificity of antibodies.
Implementation Method 1
Antibodies bind a portion of the antigen (the antigenic determinant or epitope) with the antigen combining site on the antibody
Implementation Method 2
Other components in colostrum have been shown to protect and support the antibody activity in the gastrointestinal tract
Implementation Method 3
colostrum contains lactoferrin, an iron-binding protein that prevents bacteria and viruses from obtaining iron necessary for replication
Data Source
AI summary
A composition for treatment of mucosal infection in an animal by application to a mucous membrane includes a mixture of IgY antibodies specific for a plurality of antigens obtained from a plurality of organisms, with the plurality of organisms able to cause infection of the mucous membrane. A protective matrix including non-hyperimmune colostrum can be combined with the mixture of IgY antibodies, with the protective matrix forming at least 20% by weight of the composition.